Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer mortalities in men. CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Researchers designed 1-(Indolizin-3-yl)ethan-1-ones as CBP bromodomain inhibitors for the treatment of prostate cancer. Pharmacokinetic properties evaluation were analyzed by Medicilon. Liver microsomal stability assay were performed at Medicilon. Caco-2 permeability assay was analyzed by Medicilon.

TRIM24 (tripartite motif-containing protein 24) and BRPF1 (bromodomain and PHD finger containing protein 1) are epigenetics ¡°readers¡±and potential therapeutic targets for cancer and other diseases. Y08624 (Compound 20l) is a new TRIM24/BRPF1 dual inhibitor. Y08624 displays reasonable Caco-2 permeability. Caco-2 permeability assay was performed by Medicilon.

Caco-2ϸ°ûÉø͸ÐÔÊÔÑé¿ÉÒÔÌṩÓйػ¯ºÏÎïÔÚÄ£Ä⳦µÀÌõ¼þϵÄÎüÊÕÌØÕ÷µÄÖ÷ÒªÐÅÏ¢¡£Í¨¹ýÕÉÁ¿»¯ºÏÎïͨÏ꾡°û²ãµÄÄÜÁ¦£¬ÆÀ¹ÀÆä±»ÎüÊÕµ½Ñ­»·ÏµÍ³ÖеÄDZÁ¦£¬²¢Õ¹ÍûÆäÔÚÌåÄÚµÄÒ©´ú¶¯Á¦Ñ§ÐÐΪ¡£